Hynes Keller & Hernandez, LLC is investigating potential claims against the Board of Directors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”)(NASDAQ: SPPI) arising from possible breaches of fiduciary duty by certain of its officers and directors in connection with the Company’s pursuit of Food and Drug Administration approval of its proposed bladder cancer drug apaziquone.
Shareholders interested in seeking to recover damages on behalf of SPPI and to implement corporate governance measures designed to prevent future misconduct should contact the firm.
If you hold SPPI shares and you would like to discuss your legal rights, please email the firm at info@hkh-lawfirm.com. You can also contact us by calling Michael J. Hynes at (610) 994-0292 or by sending an e-mail to mhynes@hkh-lawfirm.com.